The safety, tolerability and risks associated with the use of newer generation antidepressant drugs: a critical review of the literature.

Carvalho AF, Sharma MS, Brunoni AR, et al. Psychother Psychosom. 2016;85(5):270-288.

Boosted protease inhibitor monotherapy versus boosted protease inhibitor plus lamivudine dual therapy as second-line maintenance treatment for HIV-1-infected patients in sub-Saharan Africa (ANRS12 286/MOBIDIP): a multicentre, randomised, parallel, open-label, superiority trial.

Ciaffi L, Koulla-Shiro S, Sawadogo AB, et al. Lancet HIV. 2017;4(9):e384-e392.

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis.

Cutrell AG, Schapiro JM, Perno CF, et al. AIDS. 2021;35(9):1333–1342.

Use of Injectable CAB/RPV LA as Replacement ART in Virally Suppressed Adults With HIV.

DeHaan E, McGowan JP, Fine SM, et al, for the Medical Care Criteria Committee of the New York State Department of Health AIDS Institute. Baltimore, MD: Johns Hopkins University; 2021.

Phase 3 study of ibalizumab for multidrug-resistant HIV-1.

Emu B, Fessel J, Schrader S, et al. N Engl J Med. 2018;379(7):645-654.

Cabotegravir and rilpivirine PK following long-acting HIV treatment discontinuation.

Ford S, Crauwels H, Han K, et al. CROI. Virtual Conference; March 8-11, 2020. Abstract 466.

Switching to bictegravir/emtricitabine/tenofovir alafenamide in Black Americans with HIV-1: a randomized phase 3b, multicenter, open-label study.

Hagins D, Kumar P, Saag M, et al. J Acquir Immune Defic Syndr. 2021;88(1):86-95.

Higher rates of neuropsychiatric adverse events leading to dolutegravir discontinuation in women and older patients.

Hoffmann C, Welz T, Sabranski M, et al. HIV Med. 2017;18(1):56-63.

Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study.

Lataillade M, Lalezari JP, Kozal M, et al. Lancet HIV. 2020;7(11):e740-e751.

Efficacy and safety of dolutegravir with emtricitabine and tenofovir alafenamide fumarate or tenofovir disoproxil fumarate, and efavirenz, emtricitabine, and tenofovir disoproxil fumarate HIV antiretroviral therapy regimens started in pregnancy (IMPAACT 2010/VESTED): a multicentre, open-label, randomised, controlled, phase 3 trial.

Lockman S, Brummel SS, Ziemba L, et al. Lancet. 2021;397(10281):1276-1292.

Long-acting cabotegravir and rilpivirine after oral induction for HIV-1 infection.

Orkin C, Arasteh K, Górgolas Hernández-Mora M, et al. N Engl J Med. 2020;382(12):1124-1135.

Transgender women's concerns and preferences on potential future long-acting biomedical HIV prevention strategies: the case of injections and implanted medication delivery devices (IMDDs).

Rael CT, Martinez M, Giguere R, et al. AIDS Behav. 2020;24(5):1452-1462.

Transgender women, hormonal therapy and HIV treatment: a comprehensive review of the literature and recommendations for best practices.

Radix A, Sevelius J, Deutsch MB. J Int AIDS Soc. 2016;19(suppl 2):20810.

Depression and anxiety disorders: benefits of exercise, yoga, and meditation.

Saeed SA, Cunningham K, Bloch RM. Am Fam Physician. 2019;99(10):620-627.

Potent antiviral activity of lenacapavir in phase 2/3 in heavily ART-experienced PWH.

Segal-Maurer S, Castagna A, Berhe M, et al.  CROI. Virtual Conference; March 6-10, 2021. Abstract 127.

Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression.

Swindells S, Andrade-Villanueva JF, Richmond GJ, et al. N Engl J Med. 2020;382(12):1112-1123.

Update on neural tube defects with antiretroviral exposure in the Tsepamo study, Botswana.

Zash R, Holmes L, Diseko M, et al. J Int AIDS Soc. 2020;23(suppl 4):185-186.